Hepatic reactions during ketoconazole treatment

Area of Science:

• Hepatology
• Pharmacology
• Clinical Medicine

Background:

• Ketoconazole is an antifungal medication.
• Hepatic reactions, both silent and symptomatic, have been reported during ketoconazole therapy.
• Elevated liver enzymes can also occur in patients with fungal disease irrespective of treatment.

Purpose of the Study:

• To describe the occurrence and characteristics of hepatic reactions associated with ketoconazole treatment.
• To differentiate between silent and symptomatic hepatic reactions.
• To estimate the incidence of symptomatic hepatic reactions.

Main Methods:

• Observational analysis of ketoconazole treatment cases.
• Monitoring of liver enzyme levels (serum transaminase, alkaline phosphatase).
• Characterization of hepatic reaction timing and presentation.

Main Results:

• Silent hepatic reactions (transient asymptomatic liver enzyme elevations) can occur anytime during ketoconazole treatment.
• Asymptomatic liver enzyme increases are also observed in a significant number of untreated fungal disease patients.
• Symptomatic hepatic reactions predominantly manifest within the initial months of treatment.

Conclusions:

• Ketoconazole use is associated with potential hepatic adverse events.
• Distinguishing drug-induced liver injury from disease-related enzyme changes is crucial.
• The incidence of symptomatic ketoconazole-induced liver injury is estimated to be approximately 1 in 10,000 patients.